Rage receptor-binding molecules, conjugates thereof and their uses to detect, prevent or treat lung diseases
AssigneesVect-Horus, Universite D'Aix-Marseille, Centre National De La Recherche Scientifique
InventorsROMY COHEN, MARION DAVID, MICHEL KHRESTCHATIDKY
Life of this patent
Estimating the term…
Abstract
The invention relates to Variable Domain of Camelid Heavy Chain-only (VHH) molecules that bind RAGE and the uses thereof e.g., to transport molecules of pharmaceutical or diagnostic interest into lung cells and organs, in pathological conditions including infectious, inflammatory, cancer or rare lung diseases.
Claims17
1-16. (canceled)
A VHH molecule of formula FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein said VHH molecule binds a Receptor for Advanced Glycation Endproducts (RAGE) at the surface of a lung cell, wherein said VHH molecule comprises:
- a CDR1 sequence selected from SEQ ID NOs:
- 1, 5, 9, 13 or 17, or a variant thereof having at least 60% amino acid identity to any one of said sequences over the entire length thereof,
- a CDR2 sequence selected from SEQ ID NOs:
- 2, 6, 10, 14 or 18, or a variant thereof having at least 60% amino acid identity to any one of said sequences over the entire length thereof, and/or
- a CDR3 sequence selected from SEQ ID NOs:
- 3, 7, 11, 15 or 19, or a variant thereof having at least 60% amino acid identity to any one of said sequences over the entire length thereof.
Dependencies are inferred from the claim text.